Skip to NavigationSkip to content

BioCeramic Therapeutics appoints Ian Brown

Published on: 27/01/10

BioCeramic Therapeutics has appointed Ian Brown chief executive, taking over from Daniel Green who will remain on the board as a director.

Prior to joining BioCeramic Therapeutics, which develops novel biomaterials for healthcare, Ian held senior executive positions with Chromogenix (previously Kabi Pharmacia) in Gothenburg Sweden, Instrumentation Laboratory in Milan Italy, Cordlife, SDP Technology and Avanti Capital.

Commenting on his new appointment he said: “This is an incredibly exciting and dynamic time for BioCeramic Therapeutics. I am honoured to have the opportunity to continue BioCeramic Therapeutics’ strong leadership and commitment to serving our shareholders and employees.

“BCT stood out from the crowd with its broad pipeline and nearness to the market with a range of development programmes including bioceramics for hard tissue treatment and flexible biomimetic scaffold for tissue engineering.”

Ian has served as a non-executive director on a number of boards and as chair and deputy chair. In addition to his significant international corporate and business experience, Ian has led teams in M&A transactions and post deal integration.

His experience also covers start-ups, divestments and spinouts, as well as private and public company capital raisings and IPO’s.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches